Related Experiment Video
Updated: Jan 7, 2026
07:56
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
Published on: November 11, 2020
4.7K
Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using
Kerry Gao1,2, Nathan A Luzum1,2, Seth Cohen2
1Duke University School of Medicine, Durham, North Carolina, USA.
Summary
Optimized inhaler modifications (M2CIC and M2FP) improved drug delivery to both subglottic stenosis and bronchopulmonary regions. This dual-site targeting enhances topical therapy for patients with coexisting airway diseases.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Biomedical Engineering
Background:
- Subglottic stenosis (SGS) presents challenges for topical inhaled therapies due to distinct anatomical targets.
- Optimizing medication delivery to both the subglottic and lower airway regions is a significant therapeutic hurdle.
Purpose of the Study:
- To evaluate the efficacy of orally inhaled aerosol particles for achieving dual-site deposition in subglottic stenosis and bronchopulmonary disease.
- To assess the impact of particle size and inhaler characteristics on drug delivery to these distinct regions.
Main Methods:
- Computational modeling was employed to simulate orally inhaled drug particle delivery.
- Digitally modified airways simulated eight subglottic stenosis variants with varying lengths and luminal constrictions.
- Simulations analyzed fluticasone propionate (FP) and ciclesonide (CIC) inhaler characteristics across six particle-size distributions (M1-M3) at 15 L/min inhalation flow.
Main Results:
- Standard CIC and FP inhalers showed >80% bronchial deposition but <0.02% subglottic delivery in normal airways.
- The M2CIC modification optimized dual targeting, achieving 0.09% subglottic deposition with 69.46% bronchial efficiency.
- In SGS models, M2CIC and M2FP demonstrated balanced delivery, with subglottic deposition up to 8.4% (M2CIC) and 7.86% (M2FP), and bronchial deposition of 69.89% (M2CIC) and 61.02% (M2FP).
Conclusions:
- Inhaler modifications, specifically M2CIC and M2FP, significantly enhanced dual-site drug deposition.
- These optimized inhaler strategies support tailored therapeutic approaches for subglottic stenosis coexisting with bronchopulmonary disease.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
698
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
698
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
5.0K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
5.0K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:22Chronic Obstructive Pulmonary Disease
2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K